Wuxi Junuo, An Independent Innovative Biotechnology Company, Announced That In 2022 The American Society Of Clinical Oncology (Asco) Annual Meeting Presents The Latest Clinical Research Data Of Benoda In Poster Presentations And Online Presentations.Benoda (Ruiji Orenza Injection) Is A Cd19-Targeting Drug Independently Developed By Wuxi Ju Nuo On The Basis Of The Car-T Cell Technology Platform Of Ju Nuo Medical (A Bristol-Myers Squibb Company) Of Autologous Car-T Cell Immunotherapy Products. As Wuxi Junuo'S First Product, Benoda Was Approved By The China National Medical Products Administration In September 2021 For The Treatment Of Relapsed Or Refractory Large B Cells In Adult Patients After Second-Line Or Above Systemic Therapy Lymphoma (R/R Lbcl), Became The First Car-T Product Approved As A Class 1 Biological Product In China. Benoda Is Currently The Only Car- T Cell Immunotherapy Product In China That Has Received Three Awards At The Same Time, Including The "Major New Drug Creation" Project, The Priority Review Qualification For New Drug Marketing Applications, And The Breakthrough Therapy Drug Designation.Wuxi Junuo Is An Independent, Innovative Biotechnology Company Focused On The Development, Production And Commercialization Of Cellular Immunotherapy Products.
